Profile cover photo
Profile photo
The Cheap Investor
56 followers -
Founded in 1981 by Bill Mathews, The Cheap Investor newsletter is all about discovering quality stocks trading for less than $5 per share.
Founded in 1981 by Bill Mathews, The Cheap Investor newsletter is all about discovering quality stocks trading for less than $5 per share.

56 followers
About
Posts

Post has attachment
Oil Prices: Why so Much Volatility? - It’s one of the most volatile stories in the financial world. In August 2016, oil prices rallied from a low of $39.19 to a high of $49.36 on hopes that oil producer talks in September 2016 would curb ballooning supply. By late August, though, oil began to pull back to a low of $42.98. All as U.S. drillers added more oilrigs, as Iraq planned to increase exports of Kirkuk crude by 150,000 barrels a day, and as Nigerian rebels said they were ready for a ce...
Add a comment...

Post has attachment
Chart of Day: Groupon (GRPN) Returns 113% - The Cheap Investor has traded Groupon Inc. (GRPN) quite a few times. The most recent recommendations were at just $2.79 a share in the December 2015 issue, at $4.20 in the March 2016 issue, and at $3.35 in the July 2016 issue.  Shares have since rallied to a high of $5.94, handing subscribers potential gains of 113%, 41% and 77%.  All after the company beat EPS estimates with a one-cent loss.  Second quarter revenue jumped 2% to $756 million, whic...
Add a comment...

Post has attachment
- So much for the Federal Reserve’s idea that the U.S. economy is prepared for a rate hike… Shortly after the U.S. announced that employers added 155,000 jobs in August 2016 (missing estimates for 181,000) the odds of a September 2016 rate hike dropped to 18% from 82%. Of those jobs, some of the biggest gains were from temporary employment. Bars and restaurants added 34,000 jobs, leisure and hospitality added 29,000 jobs, and retailers added 15,100 jobs.  Meanwhile, the manufacturing secto...
Add a comment...

Post has attachment
Chart of Day: Rigel Pharmaceuticals (RIGL) soars 108% - After a sell-off in the biotech sector, we found a great deal of severely undervalued names trading at extremely low prices. It’s part of the reason why we recommended Rigel Pharmaceuticals (RIGL) at just $1.95 a share in the April 2016 issue of The Cheap Investor.  Shares of RIGL are now up 108% after the company announced favorable data on its oral spleen tyrosine kinase inhibitor, fostamatinib, for the treatment of adult chronic/per...
Add a comment...

Post has attachment
EpiPen Price Crisis: Potential Solutions for 3.6 million Americans
Add a comment...

Post has attachment
Chart of Day: Bovie Medical (BVX) Soars 159% - The summer was one of the most profitable on record for us, too.  In fact, since May, here are just some of the wins collected by subscribers: Bovie Medical Corporation (BVX) up 159% Rigel Pharmaceuticals (RIGL) up 29% Goldfield Corporation (GV) up 106% MeetMe Inc. (MEET) up 135% Adverum Biotechnologies (ADVM) up 37% Groupon Inc. (GRPN) up 77% Supreme Industries (STS) up 33% Fate Therapeutics (FATE) up 82% Trio-Tech International (TRT) up 26% I...
Add a comment...

Post has attachment
EpiPen Debate: Why Drug Delivery System is So Expensive - The pharmaceuticals industry is no stranger to controversy. Plagued with runaway drug prices that have drawn the ire of Americans, the industry has come under fire, most recently from Democratic presidential nominee Hillary Clinton. But it’s not just the high cost of drugs that’s upset her. It’s also the high cost of drug delivery systems. Rising prices for EpiPens has resulted in outrage.  When Mylan acquired the EpiPen from Merck i...
Add a comment...

Post has attachment
Chart of Day: The Biotech M&A Boom Continues - In early April 2016, we noted, “Biotech may have had a rough start to the year, lagging many other sectors. But don’t count it out just yet.  In fact, buy all you can.  The same strong catalysts and fundamentals are still firmly in place. Even though the first quarter of 2016 showed slower M&A activity, I can assure you the trend is far from over.” As it turns out, we were absolutely right. Just this week, Pfizer agreed to buy Medivation (MDVN)...
Add a comment...

Post has attachment
Hillary Clinton 2016: Where she stands on taxes - It’s looking like a nose-to-nose fight to the finish. At the moment, 41% of Americans are in favor of Hillary Clinton.  Another 37% backs Donald Trump.  About 10% are in favor of Libertarian candidate Gary Johnson, and another 4% in favor of Green Party candidate Jill Stein. But it’s the main contenders that are generating quite a firestorm about how to turn around our lackluster economy. It’s surely coming down to the wire.  Last Wednesday ...
Add a comment...

Post has attachment
Why Are Billionaires Piling Into This 4000% Growth Industry?
Add a comment...
Wait while more posts are being loaded